26 May 2013
Keywords: prosidion, begins, ph, ii, antidiabetes, drug, osi
Article | 24 January 2005
OSI Pharmaceuticals of the USA says that its UK-based subsidiary Prosidion has initiated a Phase II proof-of-concept and dose
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 January 2005
24 May 2013
© 2013 thepharmaletter.com